QuickCool is a Swedish medtech company, founded in 2003 to provide Targeted Temperature Management (TTM) solutions following cardiac arrest, stroke, and high grade fever. Its lead product, the QuickCool System, enables rapid cooling via the nasal cavity, to cool the body via the brain. QuickCool operates a lean structure typical of a startup, with three employees. The company’s scientific advisory board is chaired by TTM researcher Hans Friberg. QuickCool is listed on Aktietorget and headquartered in Lund.
The QuickCool system is the only product to cool the body via nasal access to the thermoregulatory region of the brain, allowing rapid cooling of the entire body in the event of cardiac arrest. With over 500,000 cardiac arrests each year in the US alone, we see this as a significant market opportunity, particularly in the paramedic setting.
The company awaits CE marking for its lead product, the QuickCool system, in order to begin marketing. Although the company expects to be able to do so, there is no guarantee that this will occur. There are many competitors in the Targeted Temperature Management market, although we believe that the QuickCool system has the potential (once approved) to be the best in terms of speed, portability, and ease of use. There are significant barriers to entry, however, with established methods already on the market and hence the potential for pricing pressure. Intellectual property rights risks are also significant, as with all medtech companies.